metapneumovirus

James Crowe, Jr., MD, left, and Naveenchandra Suryadevara, PhD, have discovered a monoclonal antibody with therapeutic potential that neutralizes both RSV and hMPV. (photo by Anthony Czelusniak)
August 4, 2023

Researchers discover antibody that neutralizes both RSV and hMPV

Vanderbilt and Stanford University researchers discovered a potent, cross-neutralizing human monoclonal antibody against the respiratory syncytial virus and human metapneumovirus.

By Anthony Czelusniak
February 23, 2018

Hope for an RSV vaccine

Newly discovered features in an RSV protein may be useful for rational structure-based vaccine design.

By Bill Snyder
July 23, 2014

Natural killer cells don’t clear HMPV

Understanding how the immune system responds to the respiratory virus HMPV is crucial for developing vaccines and anti-viral treatments.

By Leigh MacMillan
May 27, 2014

Respiratory virus vaccine candidate

Virus-like particles containing a protein from human metapneumovirus are a promising vaccine candidate for this respiratory virus.

By Leigh MacMillan
February 14, 2013

Research reveals clues to childhood respiratory virus

New Vanderbilt-led research published in the Feb. 14 issue of the New England Journal of Medicine has identified the relatively unknown human metapneumovirus (MPV) as the second most common cause of severe bronchiolitis in young children.

By VUMC News and Communications
September 25, 2012

Cell entry ports for cold virus

The respiratory virus HMPV uses its fusion (F) protein – which interacts with cellular receptors called integrins – to bind to and enter target cells.

By Leigh MacMillan
August 9, 2012

New therapeutic target for cold, flu viruses identified

Viruses that cause acute respiratory infections — such as human metapneumovirus (HMPV) and flu — impair a set of immune system cells that should clear the virus from the lungs. Now, Vanderbilt University investigators have discovered the signaling pathway that disables these immune cells.
By Leigh MacMillan